Listen
RIZMOIC 200 µg (naldemedine) - Constipation (OIC)
Opinions on drugs -
Posted on
Sep 10 2025
Reason for request
Modification of the listing conditions
Summary of opinion
Favourable opinion for reimbursement in the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
No clinical added value of the new form of RIZMOIC film-coated tablets in packs containing 30 tablets in unit dose blisters, compared to the forms already available.
Clinical Benefit
| Low |
The clinical benefit of RIZMOIC 200 µg (naldemedine) film-coated tablets in packs containing 30 tablets in unit dose blisters is low in the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
|
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
